Denis Arikci

Denis Arikci

Auto-generated profile, based on publicly available information

Denis Arikci

Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Journal of Psychopharmacology
Verified
Journal Article
Open access
KSKurt Stocker
Kurt Stocker
MHMatthias Hartmann
Matthias Hartmann
YSYasmin Schmid
Yasmin Schmid
SVSeverin B. Vogt
Severin B. Vogt
ABAnna M. Becker
Anna M. Becker
MLMatthias E Liechti
Matthias E Liechti
Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC remains widely used for summarizing broader experiential domains. Aims: We wanted to provide an updated, psychometrically revalidated version of the ASC. We tested whether the 42-item 11-ASC could be integrated into a coherent three-dimensional framework. We further hypothesized that this revised model would outperform the original 66-item 3D-ASC while preserving its conceptual clarity. Methods: Data from 901 5D-ASC questionnaires from 398 healthy participants across 16 randomized, mostly placebo-controlled psychedelic (lysergic acid diethylamide, psilocybin, mescaline, and N , N -dimethyltryptamine) studies were split for exploratory and confirmatory factor analysis. We compared the 3D-ASC and 11-ASC in terms of reliability and model fit, and tested whether the 11-ASC could be summarized within a three-dimensional model. Results: Ten of the 11 subscales formed three higher-order dimensions—Positive (PosE), Distressing (DisE), and Perceptual (PerE) effects—mirroring the 3D-ASC but with improved fit. We propose this as the 3D-ASCr scale. The Anxiety subscale could not be integrated due to consistent floor effects (low anxiety in the sample), but given its clinical relevance, it is retained within 3D-ASCr (as part of DisE or a standalone subscale). Conclusion: The 3D-ASCr is an updated version of the ASC and is recommended for use with classic serotonergic psychedelics in both clinical practice and research.

28 April 2025 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
JTJan Thomann
Jan Thomann
DRDeborah Rudin
Deborah Rudin
SKSelina Kraus
Selina Kraus
DADenis Arikci
Denis Arikci
FHFriederike Holze
Friederike Holze
DLDino Luethi
Dino Luethi
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is widely used recreationally and has recently gained interest as a treatment for mental health disorders. In this study, a liquid chromatography-tandem mass spectrometry method to quantify 2C-B and its metabolites 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in human plasma was developed and validated. Moreover, pharmacokinetic analysis was performed on samples from clinical study participants who received 30 mg of 2C-B. The metabolic degradation of 2C-B and its metabolites via monoamine oxidases (MAOs), cytosolic enzymes, and cytochrome P450 enzymes was assessed and their activation potencies at the serotonin 2A receptor were investigated. Optimal chromatographic separation was achieved using a Kinetex 2.6 μm XB-C18 analytical column and a mobile phase gradient of water and acetonitrile supplemented with 0.1% formic acid. Using electrospray ionization, a linear range of 0.5-100 ng/mL for 2C-B, 2.5-1000 ng/mL for BDMPAA, and 0.5-1000 ng/mL for B-2-HMPAA was achieved. The method demonstrated high accuracy, precision, and extraction recovery with minimal matrix effects. MAO-A, MAO-B, cytosolic enzymes, and CYP2D6 were identified as key enzymes involved in the metabolic degradation of 2C-B. Unlike 2C-B, BDMPAA and B-2-HMPAA did not activate the human serotonin 2A receptor, suggesting that these metabolites do not contribute to the psychedelic effect. This study provides insights into the pharmacokinetics, metabolism, and pharmacological activity of 2C-B and its metabolites. The validated liquid chromatography-tandem mass spectrometry method offers a reliable tool for future clinical studies investigating the therapeutic potential and metabolism of 2C-B. SIGNIFICANCE STATEMENT: A rapid and nonlaborious liquid chromatography-tandem mass spectrometry method was developed and validated for pharmacokinetic analysis of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolites 4-bromo-2,5-dimethoxyphenylacetic acid and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid in human plasma. To assess the metabolites' relevance in psychedelic drug action, serotonin 2A receptor activity was studied. Unlike 2C-B, the metabolites failed to activate the receptor. Monoamine oxidase A and B, and cytosolic enzymes were confirmed in 4-bromo-2,5-dimethoxyphenylacetic acid formation, whereas CYP2D6 was found to metabolize 2C-B through a minor pathway.